Trials / Completed
CompletedNCT03812510
Safety Study of A-101 Topical Solution for the Treatment of Common Warts
A Phase 3 Open Label Safety Study of A-101 Topical Solution for the Treatment of Common Warts
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 426 (actual)
- Sponsor
- Aclaris Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Not accepted
Summary
A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts
Detailed description
A Phase 3 Open Label Safety Study of A-101 Topical Solution for the Treatment of Common Warts
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | A-101 | hydrogen peroxide topical solution 45% |
Timeline
- Start date
- 2019-02-07
- Primary completion
- 2019-11-27
- Completion
- 2019-12-20
- First posted
- 2019-01-23
- Last updated
- 2020-11-23
- Results posted
- 2020-11-23
Locations
46 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03812510. Inclusion in this directory is not an endorsement.